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Background
Risperidone microspheres represents the first long-acting
injectable preparation of an atypical antipsychotic. The
Switch to Risperidone Microspheres (StoRMI) trial inves-
tigated the maintained efficacy and safety of this formula-
tion of risperidone long-acting microspheres in patients
with schizophrenia or other psychotic disorders when
swhitchingswitching from typical depot or oral neurolep-
tics to long-acting risperidone microspheres. We report
here the results of a subgroup analysis of Greek patients.
Materials and methods
Patients who were symptomatically stable on any previ-
ous antipsychotic medication for >/ = 1 month received
intramuscular injections of long-acting risperidone 25 mg
(increased to 37.5 or 50 mg, if necessary) every two weeks
for 6 months. Previous antipsychotics were continued
concomitantly during the first 3 weeks of long-acting risp-
eridone therapy.
Results
The analysis included 91 male and 31 female patients of
mean age 42.5 years. The majority of patients had schizo-
phrenia (84%; mostly paranoid according to DSM-IV cri-
teria). Other diagnoses were schizoaffective disorder (9%)
and other psychotic disorders (8%). Previous antipsy-
chotic therapy was mostly atypical antipsychotics (72%)
as well as conventional depot and oral antipsychotics.
Reasons for switching were mainly (66%) non-compli-
ance with previous therapy (66%), insufficient efficacy
(22%) and side effects (18%). The majority of patients
(77%) completed the 6-months period of therapy; most
common reasons for discontinuation were adverse events
(9%), withdrawal of consent (8%), and patients lost to
follow-up (6%). There were significant reductions from
baseline (p < 0.001) at 1, 3, and 6 months in mean scores
for the total PANSS as well as for positive, negative and
general psychopathology subscales. At endpoint, 73% of
patients had >20% improvement in PANSS total scores.
According to the Clinical Global Impression (CGI),
patients improved significantly (p < 0.001) with the group
classified as "not ill/borderline ill" rising from 2.5% at
baseline to 16% at endpoint. There were significant
improvements from baseline to endpoint (p < 0.0001) in
all components of SF-36 Quality of Life Questionnaire.
Global Assessment of Function (GAF) and patient satis-
faction also increased significantly (p < 0.0001) from
baseline. No unexpected adverse events were reported and
the ESRS total scores of ESRS were reduced significantly (p
< 0.005) from baseline at all visits.
Discussion
Switching to long-acting injectable risperidone was asso-
ciated with significant improvement of symptoms. Effi-
cacy was not only maintained but patients showed
further, significant, sustained improvement of symptoms
after switching. Patient satisfaction was significantly
higher at endpoint than at baseline.
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